On-going study and broadening of the line of applications and new interpretations of metabolic syndrome related to polycystic ovary syndrome and non-alcoholic hepatic steatosis, a large amount of material has been accumulated for assessing the genotype and phenotype in these groups of patients and who, in a second phase, will be receiving medical treatment and whose development will have to be completed with therapeutics during two years of monitoring.